Intervention

Vilanterol

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials9

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

9 shown

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDNCT07541378 · 2024-03-11

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaNCT02446418 · 2015-07-09

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02105974 · 2014-04-07

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).NCT01957150 · 2014-01-28

RELOVAIR® Lung Deflation StudyNCT01691885 · 2012-11-01

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in ChildrenNCT01573767 · 2012-04-01

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPDNCT01336608 · 2011-03-04

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent AsthmaNCT01181895 · 2010-09-01

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese SubjectsNCT00625196 · 2008-02-27

Common conditions

Asthma4 Pulmonary Disease, Chronic Obstructive4 COPD (Chronic Obstructive Pulmonary Disease)1

Leading sponsors

GlaxoSmithKline 8 Medical University of Bialystok 1

Trial status mix

COMPLETED8

SUSPENDED1

Phase mix

PHASE35

NA1

PHASE11

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.